abobotulinumtoxinA
Botulinum Toxin Type A may increase the neuromuscular blocking activities of Vecuronium.
Acetyldigitoxin
Vecuronium may increase the arrhythmogenic activities of Acetyldigitoxin.
Aclarubicin
Aclarubicin may increase the respiratory depressant activities of Vecuronium.
Advertisement
Aclidinium
Vecuronium may increase the anticholinergic activities of Aclidinium.
Alfentanil
The risk or severity of adverse effects can be increased when Vecuronium is combined with Alfentanil.
Alphaprodine
The risk or severity of adverse effects can be increased when Vecuronium is combined with Alphaprodine.
Advertisement
Ambenonium
The therapeutic efficacy of Vecuronium can be decreased when used in combination with Ambenonium.
Amikacin
Amikacin may increase the respiratory depressant activities of Vecuronium.
Apalutamide
The serum concentration of Vecuronium can be decreased when it is combined with Apalutamide.
Advertisement
Arbekacin
Arbekacin may increase the respiratory depressant activities of Vecuronium.
Atracurium
The risk or severity of adverse effects can be increased when Vecuronium is combined with Atracurium.
Atracurium Besylate
The risk or severity of adverse effects can be increased when Atracurium besylate is combined with Vecuronium.
Atropine
The risk or severity of adverse effects can be increased when Atropine is combined with Vecuronium.
Azosemide
Azosemide may decrease the neuromuscular blocking activities of Vecuronium.
Benactyzine
The risk or severity of adverse effects can be increased when Vecuronium is combined with Benactyzine.
Bendroflumethiazide
The serum concentration of Bendroflumethiazide can be increased when it is combined with Vecuronium.
Benztropine
The risk or severity of adverse effects can be increased when Benzatropine is combined with Vecuronium.
Biperiden
The risk or severity of adverse effects can be increased when Biperiden is combined with Vecuronium.
Botulinum Toxin Type A
Botulinum Toxin Type A may increase the neuromuscular blocking activities of Vecuronium.
Bumetanide
Bumetanide may decrease the neuromuscular blocking activities of Vecuronium.
Buprenorphine
The risk or severity of adverse effects can be increased when Vecuronium is combined with Buprenorphine.
Butorphanol
The risk or severity of adverse effects can be increased when Vecuronium is combined with Butorphanol.
Butylscopolamine
The risk or severity of adverse effects can be increased when Vecuronium is combined with Butylscopolamine.
Capreomycin
Capreomycin may increase the neuromuscular blocking activities of Vecuronium.
Carbamazepine
The serum concentration of Vecuronium can be decreased when it is combined with Carbamazepine.
Chlorothiazide
The serum concentration of Chlorothiazide can be increased when it is combined with Vecuronium.
Chlorphenoxamine
The risk or severity of adverse effects can be increased when Vecuronium is combined with Chlorphenoxamine.
Chlortetracycline
Chlortetracycline may increase the neuromuscular blocking activities of Vecuronium.
Chlorthalidone
The serum concentration of Chlorthalidone can be increased when it is combined with Vecuronium.
Clindamycin
Clindamycin may increase the neuromuscular blocking activities of Vecuronium.
Codeine
The risk or severity of adverse effects can be increased when Vecuronium is combined with Codeine.
Codeine Anhydrous
The risk or severity of adverse effects can be increased when Vecuronium is combined with Codeine.
CODEINE POLISTIREX
The risk or severity of adverse effects can be increased when Vecuronium is combined with Codeine.
Colistimethate
Colistimethate may increase the neuromuscular blocking activities of Vecuronium.
Cyclopenthiazide
The serum concentration of Cyclopenthiazide can be increased when it is combined with Vecuronium.
Cyclopentolate
The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Vecuronium.
Cyclosporine
Cyclosporine may increase the neuromuscular blocking activities of Vecuronium.
Dantrolene
Dantrolene may increase the neuromuscular blocking activities of Vecuronium.
Darifenacin
The risk or severity of adverse effects can be increased when Darifenacin is combined with Vecuronium.
Daunorubicin
Daunorubicin may increase the respiratory depressant activities of Vecuronium.
Demecarium
The therapeutic efficacy of Vecuronium can be decreased when used in combination with Demecarium.
Demeclocycline
Demeclocycline may increase the neuromuscular blocking activities of Vecuronium.
Deslanoside
Vecuronium may increase the arrhythmogenic activities of Deslanoside.
Desloratadine
The risk or severity of adverse effects can be increased when Desloratadine is combined with Vecuronium.
Dexetimide
The risk or severity of adverse effects can be increased when Dexetimide is combined with Vecuronium.
Dextromoramide
The risk or severity of adverse effects can be increased when Vecuronium is combined with Dextromoramide.
Dezocine
The risk or severity of adverse effects can be increased when Vecuronium is combined with Dezocine.
Dicyclomine
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Vecuronium.
Digitoxin
Vecuronium may increase the arrhythmogenic activities of Digitoxin.
Digoxin
Vecuronium may increase the arrhythmogenic activities of Digoxin.
Dihydrocodeine
The risk or severity of adverse effects can be increased when Vecuronium is combined with Dihydrocodeine.
Dihydrostreptomycin
Dihydrostreptomycin may increase the respiratory depressant activities of Vecuronium.
Diphenoxylate
The risk or severity of adverse effects can be increased when Vecuronium is combined with Diphenoxylate.
Distigmine
The therapeutic efficacy of Vecuronium can be decreased when used in combination with Distigmine.
Donepezil
The therapeutic efficacy of Vecuronium can be decreased when used in combination with Donepezil.
Doxorubicin
Doxorubicin may increase the respiratory depressant activities of Vecuronium.
Doxorubicin Hydrochloride
Doxorubicin may increase the respiratory depressant activities of Vecuronium.
Doxycycline
Doxycycline may increase the neuromuscular blocking activities of Vecuronium.
Doxycycline Anhydrous
Doxycycline may increase the neuromuscular blocking activities of Vecuronium.
Echothiophate
The therapeutic efficacy of Vecuronium can be decreased when used in combination with Echothiophate.
Edrophonium
The therapeutic efficacy of Vecuronium can be decreased when used in combination with Edrophonium.
Eluxadoline
Vecuronium may increase the constipating activities of Eluxadoline.
Epirubicin
Epirubicin may increase the respiratory depressant activities of Vecuronium.
Ethacrynate
Etacrynic acid may decrease the neuromuscular blocking activities of Vecuronium.
Ethacrynic Acid
Etacrynic acid may decrease the neuromuscular blocking activities of Vecuronium.
Ethylmorphine
The risk or severity of adverse effects can be increased when Vecuronium is combined with Ethylmorphine.
Fentanyl
The risk or severity of adverse effects can be increased when Vecuronium is combined with Fentanyl.
Fesoterodine
The risk or severity of adverse effects can be increased when Vecuronium is combined with Fesoterodine.
Framycetin
Framycetin may increase the respiratory depressant activities of Vecuronium.
Furosemide
Furosemide may decrease the neuromuscular blocking activities of Vecuronium.
Galantamine
The therapeutic efficacy of Vecuronium can be decreased when used in combination with Galantamine.
Gallamine Triethiodide
The risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Vecuronium.
Gentamicin
Gentamicin may increase the respiratory depressant activities of Vecuronium.
Ginkgo biloba extract
The therapeutic efficacy of Vecuronium can be decreased when used in combination with Ginkgo biloba.
Glucagon
The risk or severity of adverse effects can be increased when Vecuronium is combined with Glucagon recombinant.
glucagon (rDNA)
The risk or severity of adverse effects can be increased when Vecuronium is combined with Glucagon recombinant.
Glycopyrronium
Vecuronium may increase the anticholinergic activities of Glycopyrronium.
Heroin
The risk or severity of adverse effects can be increased when Vecuronium is combined with Heroin.
Homatropine
The risk or severity of adverse effects can be increased when Vecuronium is combined with Homatropine.
Human Secretin
The therapeutic efficacy of Human secretin can be decreased when used in combination with Vecuronium.
Hydrochlorothiazide
The serum concentration of Hydrochlorothiazide can be increased when it is combined with Vecuronium.
Hydrocodone
The risk or severity of adverse effects can be increased when Vecuronium is combined with Hydrocodone.
HYDROCODONE POLISTIREX
The risk or severity of adverse effects can be increased when Vecuronium is combined with Hydrocodone.
Hydroflumethiazide
The serum concentration of Hydroflumethiazide can be increased when it is combined with Vecuronium.
Hydromorphone
The risk or severity of adverse effects can be increased when Vecuronium is combined with Hydromorphone.
Hyoscyamine
The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Vecuronium.
Idarubicin
Idarubicin may increase the respiratory depressant activities of Vecuronium.
incobotulinumtoxinA
Botulinum Toxin Type A may increase the neuromuscular blocking activities of Vecuronium.
Indapamide
The serum concentration of Indapamide can be increased when it is combined with Vecuronium.
Ipratropium Bromide
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Vecuronium.
Ipratropium Bromide Anhydrous
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Vecuronium.
Isavuconazole
The serum concentration of Vecuronium can be increased when it is combined with Isavuconazole.
Isoflurophate
The therapeutic efficacy of Vecuronium can be decreased when used in combination with Isoflurophate.
Kanamycin
Kanamycin may increase the respiratory depressant activities of Vecuronium.
kanamycin A
Kanamycin may increase the respiratory depressant activities of Vecuronium.
Levomethadyl
The risk or severity of adverse effects can be increased when Vecuronium is combined with Levomethadyl Acetate.
Levorphanol
The risk or severity of adverse effects can be increased when Vecuronium is combined with Levorphanol.
Lincomycin
Lincomycin may increase the neuromuscular blocking activities of Vecuronium.
Lithium
Lithium may increase the neuromuscular blocking activities of Vecuronium.
Lithium Cation
Lithium may increase the neuromuscular blocking activities of Vecuronium.
Lumacaftor
The serum concentration of Vecuronium can be decreased when it is combined with Lumacaftor.
Magnesium Hydroxide
Magnesium hydroxide may increase the neuromuscular blocking activities of Vecuronium.
Magnesium Oxide
Magnesium oxide may increase the neuromuscular blocking activities of Vecuronium.
Magnesium Salicylate
Magnesium salicylate may increase the neuromuscular blocking activities of Vecuronium.
Magnesium Sulfate
Magnesium sulfate may increase the neuromuscular blocking activities of Vecuronium.
MAGNESIUM SULFATE ANHYDROUS
Magnesium sulfate may increase the neuromuscular blocking activities of Vecuronium.
Malathion
The therapeutic efficacy of Vecuronium can be decreased when used in combination with Malathion.
Mecamylamine
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Vecuronium.
Mefloquine
The therapeutic efficacy of Vecuronium can be decreased when used in combination with Mefloquine.
Memantine
The therapeutic efficacy of Vecuronium can be decreased when used in combination with Memantine.
Meperidine
The risk or severity of adverse effects can be increased when Vecuronium is combined with Pethidine.
Methadone
The risk or severity of adverse effects can be increased when Vecuronium is combined with Methadone.
Methadyl Acetate
The risk or severity of adverse effects can be increased when Vecuronium is combined with Methadyl Acetate.
Methantheline
The risk or severity of adverse effects can be increased when Methantheline is combined with Vecuronium.
Methixene
The risk or severity of adverse effects can be increased when Vecuronium is combined with Metixene.
Methscopolamine
The risk or severity of adverse effects can be increased when Vecuronium is combined with Methscopolamine.
Methscopolamine Bromide
The risk or severity of adverse effects can be increased when Vecuronium is combined with Methylscopolamine bromide.
Methyclothiazide
The serum concentration of Methyclothiazide can be increased when it is combined with Vecuronium.
Metoclopramide
The therapeutic efficacy of Vecuronium can be decreased when used in combination with Metoclopramide.
Metolazone
The serum concentration of Metolazone can be increased when it is combined with Vecuronium.
Metrizamide
Metrizamide may increase the respiratory depressant activities of Vecuronium.
Mianserin
Mianserin may increase the anticholinergic activities of Vecuronium.
Minaprine
The therapeutic efficacy of Vecuronium can be decreased when used in combination with Minaprine.
Minocycline
Minocycline may increase the neuromuscular blocking activities of Vecuronium.
Mirabegron
The risk or severity of adverse effects can be increased when Vecuronium is combined with Mirabegron.
Morphine
The risk or severity of adverse effects can be increased when Vecuronium is combined with Morphine.
Nabilone
Vecuronium may increase the tachycardic activities of Nabilone.
Nalbuphine
The risk or severity of adverse effects can be increased when Vecuronium is combined with Nalbuphine.
Neomycin
Neomycin may increase the respiratory depressant activities of Vecuronium.
Neostigmine
The therapeutic efficacy of Vecuronium can be decreased when used in combination with Neostigmine.
Netilmicin
Netilmicin may increase the respiratory depressant activities of Vecuronium.
Normethadone
The risk or severity of adverse effects can be increased when Vecuronium is combined with Normethadone.
O-PHENANTHROLINE
The therapeutic efficacy of Vecuronium can be decreased when used in combination with 1,10-Phenanthroline.
Octotropine Methylbromide
The risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Vecuronium.
Octylonium
The risk or severity of adverse effects can be increased when Vecuronium is combined with Otilonium.
onabotulinumtoxinA
Botulinum Toxin Type A may increase the neuromuscular blocking activities of Vecuronium.
Opium
The risk or severity of adverse effects can be increased when Vecuronium is combined with Opium.
Orphenadrine
The risk or severity of adverse effects can be increased when Orphenadrine is combined with Vecuronium.
Ouabain
Vecuronium may increase the arrhythmogenic activities of Ouabain.
Ovine Digoxin Immune Fab
Vecuronium may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).
Oxitropium
The risk or severity of adverse effects can be increased when Vecuronium is combined with Oxitropium.
Oxybutynin
The risk or severity of adverse effects can be increased when Oxybutynin is combined with Vecuronium.
Oxycodone
The risk or severity of adverse effects can be increased when Vecuronium is combined with Oxycodone.
Oxymorphone
The risk or severity of adverse effects can be increased when Vecuronium is combined with Oxymorphone.
Oxyphenonium
The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Vecuronium.
Pancuronium
The risk or severity of adverse effects can be increased when Pancuronium is combined with Vecuronium.
Pancuronium Bromide
The risk or severity of adverse effects can be increased when Pancuronium is combined with Vecuronium.
Paregoric
The risk or severity of adverse effects can be increased when Vecuronium is combined with Morphine.
Paromomycin
Paromomycin may increase the respiratory depressant activities of Vecuronium.
Pentazocine
The risk or severity of adverse effects can be increased when Vecuronium is combined with Pentazocine.
Physostigmine
The therapeutic efficacy of Vecuronium can be decreased when used in combination with Physostigmine.
Pipecuronium
The risk or severity of adverse effects can be increased when Pipecuronium is combined with Vecuronium.
Piperacillin
Piperacillin may increase the neuromuscular blocking activities of Vecuronium.
Piperacillin Anhydrous
Piperacillin may increase the neuromuscular blocking activities of Vecuronium.
Pirarubicin
Pirarubicin may increase the respiratory depressant activities of Vecuronium.
Pirenzepine
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Vecuronium.
Piretanide
Piretanide may decrease the neuromuscular blocking activities of Vecuronium.
Pirinitramide
The risk or severity of adverse effects can be increased when Vecuronium is combined with Piritramide.
Plicamycin
Plicamycin may increase the respiratory depressant activities of Vecuronium.
Polymyxin B
Polymyxin B Sulfate may increase the neuromuscular blocking activities of Vecuronium.
Polymyxin B Sulfate
Polymyxin B Sulfate may increase the neuromuscular blocking activities of Vecuronium.
Polythiazide
The serum concentration of Polythiazide can be increased when it is combined with Vecuronium.
Potassium Chloride
Vecuronium may increase the ulcerogenic activities of Potassium Chloride.
Pramlintide
Pramlintide may increase the anticholinergic activities of Vecuronium.
Procainamide
Procainamide may increase the neuromuscular blocking activities of Vecuronium.
Procyclidine
The risk or severity of adverse effects can be increased when Procyclidine is combined with Vecuronium.
Profenamine
The risk or severity of adverse effects can be increased when Ethopropazine is combined with Vecuronium.
Propantheline
The risk or severity of adverse effects can be increased when Propantheline is combined with Vecuronium.
Propantheline Bromide
The risk or severity of adverse effects can be increased when Propantheline is combined with Vecuronium.
Propiverine
The risk or severity of adverse effects can be increased when Vecuronium is combined with Propiverine.
Propoxyphene
The risk or severity of adverse effects can be increased when Vecuronium is combined with Dextropropoxyphene.
Proscillaridin
Vecuronium may increase the arrhythmogenic activities of Proscillaridin.
Pyridostigmine
The therapeutic efficacy of Vecuronium can be decreased when used in combination with Pyridostigmine.
Pyridostigmine Bromide
The therapeutic efficacy of Vecuronium can be decreased when used in combination with Pyridostigmine.
Quinethazone
The serum concentration of Quinethazone can be increased when it is combined with Vecuronium.
Quinidine
Quinidine may increase the neuromuscular blocking activities of Vecuronium.
Quinine
Quinine may increase the neuromuscular blocking activities of Vecuronium.
Ranolazine
The serum concentration of Vecuronium can be increased when it is combined with Ranolazine.
Remifentanil
The risk or severity of adverse effects can be increased when Vecuronium is combined with Remifentanil.
rimabotulinumtoxinB
Vecuronium may increase the neuromuscular blocking activities of Botulinum Toxin Type B.
Rivastigmine
The therapeutic efficacy of Vecuronium can be decreased when used in combination with Rivastigmine.
Scopolamine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Vecuronium.
Scopolamine Hydrobromide
The risk or severity of adverse effects can be increased when Scopolamine is combined with Vecuronium.
Secretin
The therapeutic efficacy of Secretin can be decreased when used in combination with Vecuronium.
Sisomicin
Sisomicin may increase the respiratory depressant activities of Vecuronium.
Solifenacin
The risk or severity of adverse effects can be increased when Vecuronium is combined with Solifenacin.
Spectinomycin
Spectinomycin may increase the respiratory depressant activities of Vecuronium.
Streptomycin
Streptomycin may increase the respiratory depressant activities of Vecuronium.
Streptozocin
Streptozocin may increase the respiratory depressant activities of Vecuronium.
Sufentanil
The risk or severity of adverse effects can be increased when Vecuronium is combined with Sufentanil.
Sulpiride
Vecuronium may increase the anticholinergic activities of Sulpiride.
Tacrine
The therapeutic efficacy of Vecuronium can be decreased when used in combination with Tacrine.
Tapentadol
The risk or severity of adverse effects can be increased when Vecuronium is combined with Tapentadol.
Tetrahydrocannabinol
Vecuronium may increase the tachycardic activities of Dronabinol.
Tiotropium
Vecuronium may increase the anticholinergic activities of Tiotropium.
Tobramycin
Tobramycin may increase the respiratory depressant activities of Vecuronium.
Tolterodine
The risk or severity of adverse effects can be increased when Tolterodine is combined with Vecuronium.
Topiramate
The risk or severity of adverse effects can be increased when Vecuronium is combined with Topiramate.
Torsemide
Torasemide may decrease the neuromuscular blocking activities of Vecuronium.
Tramadol
The risk or severity of adverse effects can be increased when Vecuronium is combined with Tramadol.
Trichlormethiazide
The serum concentration of Trichlormethiazide can be increased when it is combined with Vecuronium.
Trihexyphenidyl
The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Vecuronium.
Trihexyphenidyl Hydrochloride
The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Vecuronium.
Trimethaphan
The risk or severity of adverse effects can be increased when Trimethaphan is combined with Vecuronium.
Tropicamide
The risk or severity of adverse effects can be increased when Tropicamide is combined with Vecuronium.
Trospium
The risk or severity of adverse effects can be increased when Trospium is combined with Vecuronium.
Tubocurarine
The risk or severity of adverse effects can be increased when Tubocurarine is combined with Vecuronium.
Umeclidinium
Vecuronium may increase the anticholinergic activities of Umeclidinium.
Valrubicin
Valrubicin may increase the respiratory depressant activities of Vecuronium.
Vancomycin
Vancomycin may increase the neuromuscular blocking activities of Vecuronium.
Vemurafenib
The serum concentration of Vecuronium can be increased when it is combined with Vemurafenib.
